Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical ...

German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck KGaA has agreed to buy biotechnology company ...

As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 plexiform neurofibromas (NF1-PN) drug mirdametinib during its rolling submission, the biotech isn't wasting time in getting the ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused on developing targeted therapies for patients with severe rare diseases and ...

Following the FDA nod in late 2023, Ogsiveo (nirogacestat) became the first approved product in the company’s portfolio and the first approved drug for treating desmoid tumors, a rare, aggressive ...

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...

The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by Guggenheim on May 12, 2025. The analyst firm set a price target for $47.00 expecting SWTX to rise to within 12 months ...